Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Survey Data Reinforces Patient Benefit of Asthma Rescue Inhalers with Integrated Dose Counters



  Survey Data Reinforces Patient Benefit of Asthma Rescue Inhalers with
  Integrated Dose Counters

    Survey Finds Use of Empty Quick-Relief Inhalers Prevalent Among Asthma
                                   Patients

Business Wire

JERUSALEM -- November 8, 2013

Teva Pharmaceuticals Industries Ltd. and the Asthma and Allergy Foundation of
America (AAFA) announced today findings from a recent patient survey on
quick-relief metered dose inhaler (MDI) design. The findings will be presented
at the American College of Asthma Allergy and Immunology (ACAAI) meeting in
Baltimore, Maryland on November 7-11, 2013.

The Asthma Inhaler Design Survey was conducted to assess the behaviors,
attitudes and preferences of asthma patients with respect to rescue inhalers.
Data from 590 respondents were included in the final analysis of the survey.
Of the respondents, 48.2 percent found their quick-relief inhalers to be empty
when needed and of those, 10.4 percent had to go to the emergency room (ER)
for treatment and 20 percent had to go without treatment. When asked what they
would do to improve device functionality of their quick-relief inhalers, most
respondents said that they would add a dose counter.

“The value of a dose counter is significant. In addition to letting patients
know the number of doses remaining in case of an asthma attack, the dose
counter can provide an important signal to patients and physicians about
overall asthma control,” said Mike Tringale, M.S.M, vice president of external
affairs at AAFA. “At the time this survey was conducted, only a third of the
respondents reported current use of a rescue inhaler with a dose counter,
indicating a need for more education about the availability and benefits of an
MDI with a dose counter.”

Additional real-life observational data presented at the meeting showed that
MDIs with dose counters are associated with a reduced incidence of
respiratory-related ER visits, most likely due to a reduced risk of
sub-therapeutic dosing or empty inhalers. The dataset was extracted from the
Clinformatics™ Data Mart retrospective claims data, one of the world’s largest
healthcare databases, and included patients aged 4-64 with a diagnosis of
asthma, exercise-induced bronchospasm (EIB) or chronic obstructive pulmonary
disease (COPD). The patient population was divided into two cohorts: patients
with a prescription of albuterol MDI with dose counter and patients with a
prescription of albuterol MDI without dose counter. The incidence rate of
respiratory-related ER visits in the total study population was estimated to
be 45 percent lower in the dose counter cohort compared with the non-dose
counter cohort.

“In the U.S., asthma attacks account for nearly two million emergency
department visits each year,” said AAFA’s Inhaler Design Survey lead author
Dr. William Storms, clinical professor at the University of Colorado Health
Sciences Center and founder of the William Storms Allergy Clinic in Colorado
Springs, CO. “Due to the potential life-saving role of albuterol during an
asthma attack, it is important for patients to know the number of doses that
remain in their inhalers, since asthma attacks can occur at any time. If a
patient isn’t aware that their inhaler is empty at the time of an attack,
there is an increased risk they may end up in the ER for treatment, which
further reinforces the importance of dose counters.”

About Asthma and Allergy Foundation of America (AAFA)

The Asthma and Allergy Foundation of America (AAFA) is a not-for-profit
organization founded in 1953 that serves as the leading patient organization
for people with asthma and allergies, and the oldest asthma and allergy
patient group in the world. AAFA is dedicated to improving the quality of life
for people with asthma and allergic diseases through education, advocacy and
research. AAFA provides practical information, community-based services and
support to people through a network of regional chapters, support groups and
other local partners around the U.S. AAFA develops health education, organizes
state and national advocacy efforts and funds research to find better
treatments and cures. Visit www.aafa.org.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's leading generic drug
maker, with a global product portfolio of more than 1,000 molecules and a
direct presence in about 60 countries. Teva's branded businesses focus on CNS,
oncology, pain, respiratory and women's health therapeutic areas as well as
biologics. Teva currently employs approximately 46,000 people around the world
and reached $20.3 billion in net revenues in 2012.

Teva's Safe Harbor Statement under the U. S. Private Securities Litigation
Reform Act of 1995:

This release contains forward-looking statements, which express the current
beliefs and expectations of management. Such statements involve a number of
known and unknown risks and uncertainties that could cause our future results,
performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to such
differences include risks relating to: our ability to develop and
commercialize additional pharmaceutical products, including our ability to
develop, manufacture, market and sell biopharmaceutical products, competition
for our innovative medicines, especially Copaxone^® (including competition
from innovative orally-administered alternatives, as well as from potential
purported generic equivalents), competition for our generic products
(including from other pharmaceutical companies and as a result of increased
governmental pricing pressures), competition for our specialty pharmaceutical
businesses, our ability to achieve expected results through our specialty,
including innovative, R&D efforts, the effectiveness of our patents and other
protections for innovative products, decreasing opportunities to obtain U.S.
market exclusivity for significant new generic products, our ability to
identify, consummate and successfully integrate acquisitions and license
products, our ability to reduce operating expenses to the extent and during
the timeframe intended by our cost restructuring program, uncertainties
relating to the replacement of and transition to a new President & Chief
Executive Officer, the effects of increased leverage as a result of recent
acquisitions, the extent to which any manufacturing or quality control
problems damage our reputation for high quality production and require costly
remediation, our potential exposure to product liability claims to the extent
not covered by insurance, increased government scrutiny in both the U.S. and
Europe of our settlement agreements with brand companies and liabilities
arising from class action litigation and other third-party claims relating to
such agreements, potential liability for sales of generic medicines prior to a
final resolution of outstanding patent litigation, our exposure to currency
fluctuations and restrictions as well as credit risks, the effects of reforms
in healthcare regulation and pharmaceutical pricing and reimbursement, any
failures to comply with complex Medicare and Medicaid reporting and payment
obligations, governmental investigations into sales and marketing practices
,particularly for our specialty medicines (and our ongoing FCPA investigations
and related matters), uncertainties surrounding the legislative and regulatory
pathways for the registration and approval of biotechnology-based medicines,
adverse effects of political or economic instability, corruption, major
hostilities or acts of terrorism on our significant worldwide operations,
interruptions in our supply chain or problems with our information technology
systems that adversely affect our complex manufacturing processes, any failure
to retain key personnel or to attract additional executive and managerial
talent, the impact of continuing consolidation of our distributors and
customers, variations in patent laws that may adversely affect our ability to
manufacture our products in the most efficient manner, potentially significant
impairments of intangible assets and goodwill, potential increases in tax
liabilities resulting from challenges to our intercompany arrangements, the
termination or expiration of governmental programs or tax benefits,
environmental risks, and other factors that are discussed in our Annual Report
on Form 20-F for the year ended December 31, 2012 and in our other filings
with the U.S. Securities and Exchange Commission. Forward-looking statements
speak only as of the date on which they are made and the Company undertakes no
obligation to update or revise any forward looking statement, whether as a
result of new information, future events or otherwise.

Contact:

For Teva Pharmaceuticals Industries Ltd.
IR:
United States
Kevin C. Mannix,  215-591-8912
Ran Meir, 215-591-3033
or
Israel
Tomer Amitai,  972-3-926-7656
or
PR:
Israel
Iris Beck Codner,  972-3-926-7687
or
United States
Denise Bradley, 215-591-8974
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement